Pulmonary resection of metastatic sarcoma: Prognostic factors associated with improved outcomes

Samuel S Kim, Harald C. Ott, Cameron D. Wright, John C. Wain, Christopher Morse, Henning A. Gaissert, Dean M. Donahue, Douglas J. Mathisen, Michael Lanuti

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes. Methods: Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model. Results: Overall 5-year survival for the cohort was 50.1%. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41%; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22% versus 68%;p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival. Conclusions: Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.

Original languageEnglish (US)
Pages (from-to)1780-1787
Number of pages8
JournalAnnals of Thoracic Surgery
Volume92
Issue number5
DOIs
StatePublished - Nov 2011
Externally publishedYes

Fingerprint

Sarcoma
Metastasectomy
Lung
Survival
Neoplasm Metastasis
Disease-Free Survival
Kaplan-Meier Estimate
Reoperation
Proportional Hazards Models
General Hospitals
Patient Selection
Neoplasms
Multivariate Analysis
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary resection of metastatic sarcoma : Prognostic factors associated with improved outcomes. / Kim, Samuel S; Ott, Harald C.; Wright, Cameron D.; Wain, John C.; Morse, Christopher; Gaissert, Henning A.; Donahue, Dean M.; Mathisen, Douglas J.; Lanuti, Michael.

In: Annals of Thoracic Surgery, Vol. 92, No. 5, 11.2011, p. 1780-1787.

Research output: Contribution to journalArticle

Kim, SS, Ott, HC, Wright, CD, Wain, JC, Morse, C, Gaissert, HA, Donahue, DM, Mathisen, DJ & Lanuti, M 2011, 'Pulmonary resection of metastatic sarcoma: Prognostic factors associated with improved outcomes', Annals of Thoracic Surgery, vol. 92, no. 5, pp. 1780-1787. https://doi.org/10.1016/j.athoracsur.2011.05.081
Kim, Samuel S ; Ott, Harald C. ; Wright, Cameron D. ; Wain, John C. ; Morse, Christopher ; Gaissert, Henning A. ; Donahue, Dean M. ; Mathisen, Douglas J. ; Lanuti, Michael. / Pulmonary resection of metastatic sarcoma : Prognostic factors associated with improved outcomes. In: Annals of Thoracic Surgery. 2011 ; Vol. 92, No. 5. pp. 1780-1787.
@article{b62d256c66184835a740cd74d4d5864a,
title = "Pulmonary resection of metastatic sarcoma: Prognostic factors associated with improved outcomes",
abstract = "Background: There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes. Methods: Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model. Results: Overall 5-year survival for the cohort was 50.1{\%}. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41{\%}; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22{\%} versus 68{\%};p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival. Conclusions: Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.",
author = "Kim, {Samuel S} and Ott, {Harald C.} and Wright, {Cameron D.} and Wain, {John C.} and Christopher Morse and Gaissert, {Henning A.} and Donahue, {Dean M.} and Mathisen, {Douglas J.} and Michael Lanuti",
year = "2011",
month = "11",
doi = "10.1016/j.athoracsur.2011.05.081",
language = "English (US)",
volume = "92",
pages = "1780--1787",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Pulmonary resection of metastatic sarcoma

T2 - Prognostic factors associated with improved outcomes

AU - Kim, Samuel S

AU - Ott, Harald C.

AU - Wright, Cameron D.

AU - Wain, John C.

AU - Morse, Christopher

AU - Gaissert, Henning A.

AU - Donahue, Dean M.

AU - Mathisen, Douglas J.

AU - Lanuti, Michael

PY - 2011/11

Y1 - 2011/11

N2 - Background: There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes. Methods: Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model. Results: Overall 5-year survival for the cohort was 50.1%. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41%; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22% versus 68%;p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival. Conclusions: Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.

AB - Background: There are few data to predict the benefit of pulmonary metastasectomy in patients with extrathoracic sarcoma. This study analyzes prognostic factors associated with improved outcomes. Methods: Between June 2002 and December 2008, 97 patients underwent pulmonary resection for metastatic sarcoma at Massachusetts General Hospital. Eight patients were excluded because of lack of follow-up data. Analysis was performed using Kaplan-Meier estimates of survival, log-rank test, and multivariate Cox model. Results: Overall 5-year survival for the cohort was 50.1%. Patients who had multiple operations for recurrent pulmonary metastases had better 5-year survival compared with patients who had a single operation (69 versus 41%; p = 0.017). Median disease- free survival (DFS) for the reoperation group was 12.9 months compared with 9.1 months for the single-operation group (p < 0.028). Patients with a disease-free interval (DFI) greater than 12 months from detection of primary sarcoma to pulmonary metastasectomy had improved survival compared with those whose DFI was less than 12 months (p < 0.0001). Patients with bilateral metastasectomy had lower 5-year survival compared with metastasectomy for unilateral disease (22% versus 68%;p < 0.0001). Two or more metastases were associated with poorer outcome compared with a single metastasis (p = 0.0007). A positive resection margin portended worse survival compared with a negative resection margin (p = 0.004). Patients with lesions larger than 3 cm had decreased survival compared with patients with lesions smaller than 3 cm (p = 0.017) with no difference in median DFS. Histologic type, grade of tumor, and use of chemotherapy had no effect on survival. Multivariate analysis showed that patients with a DFI greater than 12 months (p = 0.001), single-sided metastasis (p = 0.001), negative margins (p = 0.002), and multiple operations (p = 0.018) had better survival. Conclusions: Pulmonary metastasectomy for sarcoma can be associated with prolonged survival. Tumor resectability, DFI, number of metastases, and laterality are important factors in determining patient selection for curative surgical intervention. Repeated pulmonary metastasectomy in select patients may improve survival despite recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=80155134726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155134726&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2011.05.081

DO - 10.1016/j.athoracsur.2011.05.081

M3 - Article

C2 - 22051274

AN - SCOPUS:80155134726

VL - 92

SP - 1780

EP - 1787

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -